Singapore, 31 October 2017: For the first time ever, one of the terminals at Singapore’s iconic Changi Airport will feature exclusive advertising of a single brand – Mundipharma’s BETADINE®. Travelers passing through Changi’s high-tech Terminal 4, which starts operations today, will be greeted with a range of over 100 health messages across more than 40 advanced advertising platforms.
The innovative technology adopted throughout Singapore’s eagerly-anticipated Terminal 4 such as automated check-in and facial recognition technology made it a natural fit for Mundipharma. The healthcare organisation – which has its Regional Headquarters in the city centre and is currently building a high-tech Global BETADINE® R&D Hub and Manufacturing facility in the country – is currently undergoing a digital transformation that has already included using virtual reality, augmented reality, facial mapping and apps to improve patient outcomes.
Given BETADINE® is the Official Healthcare Product Partner of Manchester City Football Club, a number of players appear in the campaign, including in an innovative multi-screen experience featuring three of the English Premier League leading Club’s stars.
Ms Teo Chew Hoon, Changi Airport Group’s Group Senior Vice President, Airside Concessions said, “Changi Airport Group is pleased to collaborate with Mundipharma, an international and well-loved brand, to launch our latest and most advanced advertising spaces in Changi Airport. Mundipharma and Changi Airport strive towards the same goals – to deliver high quality media content to our customers and enhance the communities that we serve.”
Mundipharma CEO, Raman Singh, said “We are delighted to again demonstrate our commitment to Singapore. I believe we share similar values – such as compassion, innovation and ambition – so we are proud to showcase our hero brand, BETADINE®, in one of Singapore’s crown jewels, Changi Airport.
“In an early milestone for BETADINE®, it was used to disinfect NASA’s Apollo 11 spacecraft after the first moon landing. This unique partnership with the world’s number one airport is another aeronautical chapter in the rich history of our brand,” added Mr Singh.
About Changi Airport Group
Changi Airport Group (Singapore) Pte Ltd (CAG) (www.changiairportgroup.com) was formed on 16 June 2009 and the corporatisation of Singapore Changi Airport (IATA: SIN, ICAO: WSSS) followed on 1 July 2009. As the company managing Changi Airport, CAG undertakes key functions focusing on airport operations and management, air hub development, commercial activities and airport emergency services. CAG also manages Seletar Airport (IATA: XSP, ICAO: WSSL) and through its subsidiary Changi Airports International, invests in and manages foreign airports.
Changi Airport is the world’s sixth busiest airport for international traffic. It served a record 58.7 million passengers from around the globe in 2016. Including Terminal 4, Changi Airport has 400 retail and service stores, as well as 140 F&B outlets. With over 100 airlines providing connectivity to 380 cities worldwide, Changi Airport handles about 7,000 flights every week, or about one every 90 seconds.
Mundipharma’s independent associated companies are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
For more information please visit: www.mundipharma.com.sg
The BETADINE® range of medicines containing Povidone-Iodine is trusted by hospitals around the world for over 60 years to prevent and treat infections. A trusted brand among consumers at home to treat small wounds and grazes, sore throats, feminine infections and to stop minor problems from escalating into big issues. In-vitro studies show that BETADINE® medicines containing Povidone-Iodine kill a broad range of bacteria, viruses and fungi including antibiotic-resistant strains that cause infections. BETADINE® has four main categories of products in Wound Care, Feminine Care, Throat / Oral Care and Infectious Diseases to meet the varying needs of our customers.
®: BETADINE is a registered trademark of Mundipharma
For further information about Changi Airport Group please contact:
Ng Koon Ling (Ms)
Senior Manager, Corporate and Marketing Communications
+65 6595 6843
For further information about Mundipharma please contact:
Head of Communications & Digital Strategy –
Asia Pacific, Middle East, Africa & Latin America
+65-6303-9732 | email@example.com